Therefore, guidelines generally advocate first-line palliative treatment with platinum/etoposide for metastatic GEP-NEC [15–18], whereas the optimal treatment for GEP-NET G3 and NEC with Ki-67 ≤ 55% remains uncertain [19, 20]. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.